Price
$24.25
Increased by +0.01%
Dollar Volume (20D)
8.74 M
ADR%
5.86
Earnings Report Date (estimate)
Aug 2, 23 (-1.65)
Market Cap.
1.29 B
Shares Float
40.56 M
Shares Outstanding
53.40 M
Beta
1.75
Price / Earnings
-3.96
BPR
4.68
20D Range
21.21 25.30
50D Range
21.21 29.06
200D Range
21.21 57.96
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 5, 23 -1.54
Decreased by -28.33%
-1.51
Decreased by -1.32%
Feb 23, 23 -1.56
Decreased by -56.00%
-1.22
Decreased by -22.84%
Nov 8, 22 -1.24
Decreased by -31.91%
-1.13
Decreased by -8.61%
Aug 4, 22 -1.32
Decreased by -28.16%
-1.04
Decreased by -25.89%
May 5, 22 -1.20
Decreased by -42.86%
-0.89
Decreased by -39.14%
Feb 28, 22 -1.00
Decreased by -1.01%
-0.79
Decreased by -33.65%
Nov 3, 21 -0.94
Decreased by -18.99%
2.30
Decreased by -61.25%
Aug 5, 21 -1.03
Decreased by -58.46%
-0.86
Decreased by -22.99%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 32.50 M
Increased by +34.30%
-80.80 M
Decreased by -27.44%
Decreased by -248.62%
Increased by +5.10%
Dec 31, 22 38.00 M
Increased by +48.26%
-79.90 M
Decreased by -50.58%
Decreased by -210.26%
Decreased by -1.57%
Sep 30, 22 30.30 M
Increased by +226.34%
-66.20 M
Decreased by -41.60%
Decreased by -218.48%
Increased by +56.61%
Jun 30, 22 31.30 M
Increased by +464.53%
-70.00 M
Decreased by -39.20%
Decreased by -223.64%
Increased by +75.34%
Mar 31, 22 24.20 M
Increased by +336.87%
-63.40 M
Decreased by -54.77%
Decreased by -261.98%
Increased by +64.57%
Dec 31, 21 25.63 M
Increased by +1.06 K%
-53.06 M
Decreased by -27.72%
Decreased by -207.02%
Increased by +88.95%
Sep 30, 21 9.28 M
Increased by +22.22%
-46.75 M
Decreased by -51.69%
Decreased by -503.53%
Decreased by -24.12%
Jun 30, 21 5.54 M
Decreased by -3.54%
-50.29 M
Decreased by -99.35%
Decreased by -907.01%
Decreased by -106.66%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.